Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Adjunctive Thymoglobulin with Proteasome Inhibitor Based Treatment of Late Mixed Acute Rejection.
A. Lichvar,¹ A. Leino,¹ S. Tremblay,¹ A. Shields,² F. Paterno,¹ A. Govil,¹ M. Anand,¹ T. Diwan,¹ J. Kremer,² R. Alloway,¹ E. Woodle.¹
¹University of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati
Proteasome inhibitor (PI) containing regimens treat mixed acute rejection (MAR) at least in part due to elimination of donor specific antibody (DSA) and via effects…
2017 American Transplant Congress
Race, Admissions, and Renal Transplant Waitlisting.
R. Lynch, R. Zhang, R. Patzer, C. Larsen, A. Adams.
Surgery, Emory University, Atlanta, GA
Background: We have previously shown that increased hospitalization while listed for renal transplantation is associated with excess waitlist mortality, reduced odds of transplantation, and inferior…
2017 American Transplant Congress
Lower Mean Tacrolimus Troughs Increase Risk of De Novo Donor-Specific Antibodies in the First Year of Kidney Transplant.
S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.
University of Colorado, Aurora, CO
Development of de novo donor-specific antibodies (dnDSA) is the first step in the evolution of antibody-mediated rejection, which constitutes the leading cause of death-censored graft…
2017 American Transplant Congress
Significant Allosensitisation Despite Early, within 24 Hour, Graft Nephrectomy.
G. Lucisano,¹ P. Brookes,² E. Santos-Nunez,² N. Firmin,² N. Gunby,² S. Hassan,¹ A. Gueret-Wardle,¹ M. Willicombe,¹ D. Taube.¹
¹Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; ²Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom
Introduction: Although it is well known that allograft nephrectomy (Nx) is followed by the development of donor-specific antibodies (DSAs) even after a short transplant period,…
2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…
2017 American Transplant Congress
Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.
H. Holdaas,¹ S. Chadban,¹ J. de Fijter,¹ L. Rostaing,¹ U. Mancilla,¹ P. Lopez,² G. Bader,² J. Cruzado,¹ M. van der Giet.¹
¹ELEVATE Study Group, Oslo, Norway; ²Novartis Pharma AG, Basel, Switzerland
Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…
2017 American Transplant Congress
Relationship Between Mixed Chimerism and Tolerance in HLA-Matched and -Mismatched Recipients of Kidney and Hematopoietic Cell Transplants.
S. Busque, J. Scandling, J. Shizuru, R. Lowsky, A. Shori, J. Kent, E. Engleman, S. Strober.
Stanford University, Stanford
Twenty-eight fully HLA-matched and 18 HLA haplotype- matched recipients were given combined kidney and hematopoietic cell transplants using a completely post-transplant conditioning regimen consisting of…
2017 American Transplant Congress
APOL1 Genotype Does Not Affect Donor Renal Function Post Live Kidney Donation.
K. Koutroutsos,¹ R. Sergeant,² F. Powell,² C. Freeman,² R. Charif,¹ J. Galliford,¹ P. Brookes,² D. Taube,¹ M. Loucaidou.¹
¹Kidney and Transplant Center, Imperial College Healthcare NHS Trust, London, United Kingdom; ²Histocompatibility and Immunogenetics Laboratory, Imperial College Healthcare NHS Trust, London, United Kingdom
Background: Apolipoprotein-L1 (APOL1) risk variants have emerged as a predictor of renal disease in individuals of African Ancestry (AA). The effect of APOL1 risk variants…
2017 American Transplant Congress
Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.
C. Lefaucheur,¹ B. Sis,² D. Viglietti,¹ L. Hidalgo,² O. Aubert,¹ D. Glotz,¹ C. Legendre,¹ A. Zeevi,³ P. Halloran,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Alberta, Edmonton, Canada; ³University of Pittsburgh Medical Center, Pittsburgh
Addressing the heterogeneity of antibody-mediated allograft rejection by identifying phenotypes based on pathophysiology is critical for improving outcomes in transplantation. We investigated whether complement-binding anti-HLA…
2017 American Transplant Congress
Donor Warm Ischemic Time >80min Is an Important Predictor of Kidney Graft Survival from Donors After Cardiac Death.
J. Chen,¹ D. Mikhail,² H. Sharma,³ A. Hijazi,¹ D. Nap,¹ L. Stitt,⁴ J. Jevnikar,⁵ M. Cooper,⁶ P. Luke,² A. Sener.²
¹Schulich School of Medicine & Dentistry, London, Canada; ²Urology, Western University, London, Canada; ³General Surgery, Western University, London, Canada; ⁴LW Stitt Statistical Services, London, Canada; ⁵Engineering, Ryerson University, Toronto, Canada; ⁶Georgetown University, Washington
We analyzed UNOS data to determine how donor warm ischemic time (WIT), donor BMI, donor hypertension (dHTN), cold ischemic time (CIT), and vasopressin use in…